Barnett Valerie, Chief Legal Officer, has demonstrated a consistent pattern of selling activity in Cytek Biosciences, Inc. (CTKB) based on SEC Form 4 filings. Over 26 reported transactions, all have been sales, with no recorded purchases, resulting in a total sell value of $130,972.79. The majority of these transactions occurred in 2025 and 2026, with notable sales on March 10, 2026 ($24,280.20, $17,964.81, and $7,449.03), February 18, 2026 ($2,205), and November 18, 2025 ($19,338.41, $13,753.11, $6,547.52, and $3,588.97). Earlier sales in August 2025 included transactions valued at $14,652.54, $12,180, $5,822.04, and $3,191.16.
This activity reveals a clear selling bias, with Barnett consistently reducing their holdings in CTKB over time. The transactions span multiple dates, suggesting a methodical approach to divestment rather than a single large-scale sale. Notably, all sales were classified under transaction codes "F" (representing dispositions under Rule 16b-3) and "M" (exercise of derivative securities), indicating compliance with regulatory frameworks for insider transactions. While the reasons behind these sales are not disclosed, the data underscores a sustained trend of reducing equity exposure in CTKB, reflecting Barnett’s ongoing financial decisions as an insider.
AI-assisted summary